Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
1,763
Views
14
CrossRef citations to date
0
Altmetric
Research Paper

MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma

Hui Liua Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, ChinaView further author information
,
Zuofei Chib Department of Pediatric Hematology, Shengjing Hospital of China Medical University, Shenyang, ChinaView further author information
,
Hong Jinc Department of Pathogenic Biology, College of Basic Medical Science, China Medical University, Shengyang, ChinaView further author information
&
Wei Yanga Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1730-8648View further author information
ORCID Icon
Pages 1611-1626 | Received 09 Feb 2021, Accepted 17 Apr 2021, Published online: 04 May 2021

References

  • Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–65.
  • Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–741.
  • Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet. 2009;374:324–339.
  • Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998;104:439–444.
  • Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
  • Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
  • Mey UJ, Leitner C, Driessen C, et al. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol. 2016;34:217–223.
  • Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–858.
  • Rovira C, Güida MC, Cayota A. MicroRNAs and other small silencing RNAs in cancer. IUBMB Life. 2010;62:859–868.
  • Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–179.
  • Wong KY, Yim RL, So CC, et al. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood. 2011;118:5901–5904.
  • Wong KY, Liang R, So CC, et al. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol. 2011;154:569–578.
  • Bi C, Chung TH, Huang G, et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6:26508–26518.
  • Peng Y, Shen X, Jiang H, et al. miR-188-5p suppresses gastric cancer cell proliferation and invasion via targeting ZFP91. Oncol Res. 2018;27:65–71.
  • Fang F, Chang RM, Yu L, et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63:874–885.
  • Zhang H, Qi S, Zhang T, et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015;6:6092–6104.
  • Li N, Shi H, Zhang L, et al. miR-188 inhibits glioma cell proliferation and cell cycle progression through targeting β-catenin. Oncol Res. 2018;26:785–794.
  • Wu J, Lv Q, He J, et al. MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes. Cell Commun Signal. 2014;12:66.
  • Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–159.
  • Liu H, Wang H, Wu B, et al. Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma. Clin Exp Pharmacol Physiol. 2017;44:1032–1041.
  • Mohammed MK, Shao C, Wang J, et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3:11–40.
  • Kornmann M, Ishiwata T, Beger HG, et al. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene. 1997;15:1417–1424.
  • Xiao M, Jia S, Wang H, et al. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol. 2013;139:661–667.
  • Zhang H, Wei Q, Liu R, et al. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS ONE. 2014;9:e91069.
  • Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15:3463–3469.
  • Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220–5227.
  • Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003;17(20):2481–2495.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.